Systemic Inflammatory Response and Chemotherapy Efficacy in Non-Small Cell Lung Cancer: An Analysis of the Platelet-to-Lymphocyte Ratio as a Predictive Biomarker
DOI:
https://doi.org/10.37275/bsm.v9i8.1365Keywords:
Chemotherapy, Non-small cell lung cancer, Platelet-to-lymphocyte ratio, Prognosis, Systemic inflammationAbstract
Background The variable response to chemotherapy in non-small cell lung cancer (NSCLC) necessitates accessible biomarkers for prognostic stratification. The platelet-to-lymphocyte ratio (PLR), a marker of systemic inflammation, is a promising candidate. This study evaluates the predictive value of pre-treatment PLR for chemotherapy response in an Indonesian NSCLC cohort, a population underrepresented in biomarker research.
Methods: A retrospective cohort study was conducted on 59 adult patients with advanced-stage NSCLC at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Patients receiving first-line platinum-based chemotherapy were included. The association between baseline hematological markers and chemotherapy response (Partial Response [PR], Stable Disease [SD], Progressive Disease [PD]) was analyzed using the Kruskal-Wallis test, with Dunn's test for post-hoc comparisons. Receiver Operating Characteristic (ROC) curve analysis was used to determine the predictive accuracy and an optimal cut-off value for PLR.
Results: Statistically significant differences in median PLR were found across all response groups (p-value <0.0001). Post-hoc analysis confirmed a graded response, with the PLR of the PD group being significantly higher than that of both the SD and PR groups. ROC analysis demonstrated good predictive accuracy for PLR in discriminating responders (PR) from non-responders (SD+PD), yielding an Area Under the Curve (AUC) of 0.86. A PLR cut-off of 185 was identified, showing high sensitivity and specificity.
Conclusion: In this cohort, pre-treatment PLR was a statistically robust predictor of chemotherapy response, with a clear dose-response relationship and good predictive accuracy. PLR reflects the crucial balance between tumor-driven inflammation and host immunity, and its elevation signals a biological state that is resistant to standard chemotherapy. This simple, inexpensive biomarker holds considerable potential as a component of a multi-faceted prognostic model for NSCLC.
Authors
- Sudarto1*
- Ade Pratama Heriansa2
- 1Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
- 2Resident in Internal Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
Corresponding author Sudarto — sudartokurnia@yahoo.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
